Mammoth Biosciences released nonhuman primate data for its lead program: a gene editing therapy designed to durably lower triglycerides. The preclinical monkey results showed on‑target editing and biomarker changes consistent with triglyceride reduction, supporting the company’s plan to advance toward first‑in‑human testing. The data represent a milestone for in vivo gene editing efforts aimed at cardiometabolic endpoints and add to a growing pipeline of programs from CRISPR‑era startups seeking durable metabolic risk reduction via a single administration.